Media
-
Switzer TV | Stocks slide, is now the time to buy anyway? Red flags for SpaceX IPO
Daniel Tillett, Racura Oncology: the Australian biotech that says it has cracked a cancer target left untouched for 40 years, and why its shareholders keep backing it. Watch here.
-
Panel Discussion: “Unlocking Investment in Life Sciences” – Ignite Investment Summit, Singapore
Racura Oncology CEO Dr Daniel Tillett discusses how to unlock investment in Life Sciences organisations, alongside Andrew Er, Managing Director at Quantum Health, Dr Julian Chick, Principal at Kobold Capital. Watch here.
-
Racura Oncology Presents Key MYC Silencing Data at Major Cancer Conference
ShareCafe: Racura Oncology Ltd (ASX: RAC) has announced the presentation of significant mechanism of action data concerning its lead asset, (E,E)-bisantrene, at the prestigious 2026 American Association of Cancer Research (AACR) Annual Meeting. Read the article here.
-
Long Shortz with Racura: Tackling MYC-driven cancer pathways
Host Tylah Tully sits down with Racura Oncology (ASX:RAC) Executive Chair Dr Pete Smith to discuss the company’s HARNESS-1 lung cancer trial. Watch the video here
-
Racura teams with Purdue Uni to advance cancer drug candidate
Racura and Purdue University in US partner for molecular level studies on how (E,E)-bisantrene binds to the MYC-G4 DNA structure. Read the full article here.
-
Long Shortz with Racura: Lung cancer trial edges closer to patient enrolment
Host Tylah Tully sits down with Racura Oncology (ASX:RAC) CEO Dr Daniel Tillett to discuss the company’s upcoming HARNESS-1 lung cancer trial. Watch the video here.
-
Pioneering Aussie biotechs pass the clinical test
The performance of the ASX life sciences sector during the reporting season is a precautionary tale about not trusting statistics – or at least not relying on them at face value. Read article here
-
Racura scientists develop cardioprotection blood test to support key trial
Racura Oncology scientists have developed a novel blood-based molecular test designed to assess the cardioprotective effects of its lead drug candidate RC220. Read article here.
-
Long Shortz with Racura: Unlocking major IP and clinical milestones in transformative quarter
Host Tylah Tully sits down with Racura Oncology (ASX:RAC) executive director Peter Smith who talks through the company’s transformative quarter, marked by major intellectual property, clinical and funding milestones. Watch the interview here.
